Dr. Xinliang Mao
My Social Links

Dr. Xinliang Mao

Professor
Soochow University, China

Highest Degree
Ph.D. in Pharmacology and Toxicology from Beijing University, Beijing, China

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Anti-Cancer Drug Discovery
62%
Cancer Pharmacology
90%
Hematology
75%
Leukemia
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Zhu, J., P. Pan, Y. Li, M. Wang and D. Li et al., 2014. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors. Mol. Biosyst. 10.1039/C3MB70314B.
    CrossRef  |  Direct Link  |  
  2. Zhang, Z., X. Du, C. Zhao, B. Cao, Y. Zhao and X. Mao, 2013. The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma. Anticancer Drugs, 24: 792-798.
    CrossRef  |  PubMed  |  
  3. Zhang, J., J. Tang, B. Cao, Z. Zhang and J. Li et al., 2013. The natural pesticide dihydrorotenone induces human plasma cell apoptosis by triggering endoplasmic reticulum stress and activating p38 signaling pathway. PLoS One, Vol. 8. 10.1371/journal.pone.0069911.
    CrossRef  |  Direct Link  |  
  4. Yin, S.Q., M. Shi, T.T. Kong, C.M. Zhang and K. Han et al., 2013. Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro. Bioorg. Med. Chem. Lett., 23: 3314-3319.
    CrossRef  |  PubMed  |  
  5. Yin, S.Q., C.F. Zhang, X. Mao and Z.P. Liu, 2013. An efficient synthesis of (R)- and (S)-8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene. Tetrahedron Asymmetry, 24: 230-323.
    CrossRef  |  Direct Link  |  
  6. Mao, X., 2013. Targeting the ubiquitin-proteasome pathway--current perspectives and future directions. Curr. Pharm. Des., 19: 3173-3174.
    CrossRef  |  PubMed  |  
  7. Li, J., J. Zhu, B. Cao and X. Mao, 2013. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Curr. Pharm. Des. .
    PubMed  |  
  8. Li, J., B. Cao, S. Zhou, J. Zhu, Z. Zhang, J. Hou and X. Mao, 2013. Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling. Eur. J. Hematol., 91: 514-521.
    CrossRef  |  Direct Link  |  
  9. Chen, G., K. Han, X. Xu, X. Du and Z. Zhang et al., 2013. An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway. Br. J. Cancer. 10.1038/bjc.2013.711.
    CrossRef  |  Direct Link  |  
  10. Cao, B., J. Li, J. Zhu, M. Shen and K. Han et al., 2013. The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity. J. Biol. Chem., 288: 34181-34189.
    CrossRef  |  PubMed  |  
  11. Cao, B., J. Li and X. Mao, 2013. Dissecting bortezomib: Development, application, adverse effects and future direction. Curr. Pharm. Des., 19: 3190-3200.
    CrossRef  |  PubMed  |  
  12. Zhu, J., Y. Li, H. Yu, L. Zhang, X. Mao and T. Hou, 2012. Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses. Comb. Chem. High Throughput. Screen., 15: 439-450.
    CrossRef  |  PubMed  |  
  13. Ling, C., G. Chen, G. Chen, Z. Zhang and B. Cao et al., 2012. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo. Int. J. Cancer, 131: 2411-2419.
    CrossRef  |  PubMed  |  Direct Link  |  
  14. Mao, X., T. Hou, B. Cao, W. Wang and Z. Li et al., 2011. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: In vitro and in silico evidence. Mol. Pharmacol., 79: 672-680.
    CrossRef  |  PubMed  |  
  15. Mao, X., B. Cao, T.E. Wood, R. Hurren and J. Tonget al., 2011. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood, 117: 1986-1997.
    CrossRef  |  PubMed  |  
  16. Gan, F., B. Cao, D. Wu, Z. Chen, T. Hou and X. Mao, 2011. Exploring old drugs for the treatment of hematological malignancies. Curr. Med. Chem., 18: 1509-1514.
    CrossRef  |  PubMed  |  
  17. Xu, G.W., M. Ali, T.E. Wood, D. Wong and N. Maclean et al., 2010. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood, 115: 2251-2259.
    CrossRef  |  PubMed  |  
  18. Wood, T.E., S. Dalili, C.D. Simpson, M.A. Sukhai and R. Hurren et al., 2010. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol. Cancer Ther., 9: 246-256.
    CrossRef  |  PubMed  |  
  19. Li, X., T.E. Wood, R, Sprangers, G. Jansen and N.E. Franke et al., 2010. Effect of noncompetitive proteasome inhibition on bortezomib resistance. J. Natl. Cancer Inst., 102: 1069-1082.
    CrossRef  |  PubMed  |  
  20. Tiedemann, R.E., J. Schmidt, J.J. Keats, C.X. Shi and Y.X. Zhu et al., 2009. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood, 113: 4027-4037.
    CrossRef  |  PubMed  |  
  21. Ren, X., X. Mao, L. Cao, K. Xue and L. Si et al., 2009. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. Eur. J. Pharm. Sci., 36: 401-411.
    CrossRef  |  PubMed  |  
  22. Mao, X., X. Li, R. Sprangers, X. Wang and A. Venugopal et al., 2009. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia, 23: 585-590.
    CrossRef  |  PubMed  |  
  23. Zhu, X., X. Mao, R. Hurren, A.D. Schimmer, S. Ezzat and S.L. Asa, 2008. Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. J. Clin. Endocrinol. Metab., 93: 3610-3617.
    CrossRef  |  PubMed  |  
  24. Wood, T.E., S. Dalili, C.D. Simpson, R. Hurren and X. Mao et al., 2008. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol. Cancer Ther., 7: 3546-3555.
    CrossRef  |  PubMed  |  
  25. Tiedemann, R.E., X. Mao, C.X. Shi, Y.X. Zhu and S.E. Palmer et al., 2008. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J. Clin. Invest., 118: 1750-1764.
    CrossRef  |  PubMed  |  
  26. Sprangers, R., X. Li, X. Mao, J.L. Rubinstein, A.D. Schimmer and L.E. Kay, 2008. TROSY-Based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry, 47: 6727-6734.
    CrossRef  |  PubMed  |  Direct Link  |  
  27. Ren, X., X. Mao, L. Si, L. Cao and H. Xiong et al., 2008. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur. J. Pharm. Biopharm., 70: 279-288.
    CrossRef  |  PubMed  |  
  28. Mao, X., X. Zhu, R. Hurren, S. Ezzat and A.D. Schimmer, 2008. Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. Leuk. Res., 32: 1480-1482.
    CrossRef  |  PubMed  |  Direct Link  |  
  29. Mao, X., S.B. Liang, R. Hurren, M. Gronda and S. Chow et al., 2008. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood, 112: 760-769.
    CrossRef  |  PubMed  |  
  30. Mao, X. and A.D. Schimmer, 2008. The toxicology of Clioquinol. Toxicol. Lett., 182: 1-6.
    CrossRef  |  PubMed  |  
  31. Mao, X., A.K. Stewart, R. Hurren, A. Datti and X. Zhu et al., 2007. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood, 110: 4047-4054.
    PubMed  |  
  32. Yip, K.W., X. Mao, P.Y. Au, D.W. Hedley and S. Chow et al., 2006. Benzethonium chloride: A novel anticancer agent identified by using a cell-based small-molecule screen. Clin. Cancer Res., 12: 5557-5569.
    PubMed  |  
  33. Yip, K.W., E. Ito, X. Mao, P.Y. Au and D.W. Hedley et al., 2006. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol. Cancer Ther., 5: 2234-2240.
    PubMed  |  
  34. Mao, X., E. Seidlitz, R. Truant, M. Hitt and H.P. Ghosh, 2004. Re-Expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene, 23: 5632-5642.
    PubMed  |  
  35. Mao, X., E. Seidlitz, K. Ghosh, Y. Murakami and H.P. Ghosh, 2003. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res., 63: 7979-7985.
    PubMed  |  
  36. Mao, X., T. Kashii, R. Hayashi, K. Sassa and T. Fujishita et al., 2000. Cloning of differentially expressed sequence tags from nickel-transformed human embryonic lung cells. Cancer Lett., 161: 57-62.
    PubMed  |  Direct Link  |